Table 1 Patient characteristics and outcomes in the entire AMLM7 and AMLM12 cohorts
AMLM7 (n = 256) | AMLM12 (n = 422) | p-valuea | |
|---|---|---|---|
Age, median years (IQR) | 43.4 (31.6–51.6) | 48.1 (38.4–55.2) | <0.001 |
Male gender (%) | 55.1 | 57.1 | 0.6 |
ECOG PS > 0 (%) | 50.0 | 54.9 | 0.2 |
Cytogenetics, n (%) | 0.2 | ||
Intermediate | 201 (78.5) | 338 (80.1) | |
Adverse | 39 (15.2) | 70 (16.6) | |
Unknown | 16 (6.3) | 14 (3.3) | |
WCC (x 10 9 /L), median (IQR) | 10.6 (3.3–43.5) | 10.0 (2.9–33.7) | 0.3 |
>40 × 109/L (%) | 26.2 | 21.6 | 0.2 |
>100 × 109/L (%) | 10.5 | 6.6 | 0.082 |
Febrile (%) | 30.1 | 29.1 | 0.8 |
Bleeding (%) | 22.3 | 12.8 | 0.002 |
DIC (%) | 4.7 | 3.1 | 0.3 |
G-CSF (%) | 80.1 | 96.7 | <.001 |
>1 induction cycle, n (%) | 19 (7.4) | 41 (9.7) | 0.3 |
CR—after 1 cycle (%) | 75.4 | 76.3 | 0.8 |
CR—total (%) | 79.7 | 82.5 | 0.4 |
Randomized to standard IcE, n (%) | 87 (34.0) | 146 (34.6) | 0.9 |
Received 2 cycles of standard IcE | 81 (93.1) | 125 (85.6) | 0.7 |
Early mortality, n (%) | |||
30-day mortality | 30 (11.7) | 18 (4.3) | <0.001 |
60-day mortality | 36 (14.1) | 30 (7.1) | 0.005 |
90-day mortality | 40 (15.6) | 34 (8.1) | 0.003 |
Allogeneic SCT, n (%) | 76 (29.7) | 215 (51.3) | <0.001 |
Transplant in first CR | 32 (12.5) | 120 (28.4) | <0.001 |
Transplant other status | 44 (17.2) | 95 (22.5) | 0.12 |
Autologous SCT, n (%) | 25 (9.8) | 7 (1.7) | <0.001 |
